公开(公告)号：EP3175855A1

公开(公告)日：2017-06-07

申请号：EP16196645.2

申请日：2005-03-14

申请人： Intercept Pharmaceuticals, Inc.

发明人： FIORUCCI, Stefano ,  PELLICCIARI, Roberto ,  PRUZANSKI, Mark

IPC分类号： A61K31/56

摘要： The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the famesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

摘要翻译： 本发明涉及用于抑制在表达法呢醇X受体（FXR）的器官中发生的纤维化的方法。 该方法包括将有效量的FXR的高效活化配体给予未患胆汁淤积病症的患者的步骤。 本发明还提供了含有有效量的FXR配体的药物组合物和用于分配药物组合物的试剂盒。

公开(公告)号：EP2712617B1

公开(公告)日：2016-11-02

申请号：EP13189553.4

申请日：2005-03-14

申请人： Intercept Pharmaceuticals, Inc.

发明人： Fiorucci, Stefano ,  Pelliciari, Roberto ,  Pruzanski, Mark

IPC分类号： A61K31/56

摘要： The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

摘要翻译： 本发明涉及在法尼酯X受体（FXR）表达的器官中发生的抑制纤维化的方法。 该方法包括向没有患有胆汁淤积状况的患者施用有效量的高效力FXR激活配体的步骤。 本发明还提供含有有效量的FXR配体的药物组合物和用于分配药物组合物的试剂盒。

公开(公告)号：EP2925328A1

公开(公告)日：2015-10-07

申请号：EP13802822.0

申请日：2013-11-26

申请人： Intercept Pharmaceuticals, Inc.

发明人： PRUZANSKI, Mark ,  ADORINI, Luciano

IPC分类号： A61K31/575 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P35/00

CPC分类号： A61K31/575 ,  C07J9/005 ,  C07J31/006 ,  C07J41/0055

摘要： The present invention relates to methods of treating, reducing the risk of preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by using a compound of formula A: or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及通过使用式（A）的化合物治疗，降低，预防或缓解肺部疾病或病症的风险，减少或抑制肺中的炎症和促进肺修复的方法： 或其药学上可接受的盐。

公开(公告)号：EP2324046B1

公开(公告)日：2014-09-03

申请号：EP09791016.0

申请日：2009-07-30

申请人： Intercept Pharmaceuticals, Inc.

发明人： PELLICCIARI, Roberto

IPC分类号： C07J31/00 ,  A61K31/575 ,  A61P1/16 ,  A61P13/12 ,  A61P37/00

CPC分类号： C07J31/006 ,  A61K31/575 ,  C07J9/00 ,  C07J31/00

公开(公告)号：EP2040713B1

公开(公告)日：2014-06-18

申请号：EP07809913.2

申请日：2007-06-27

申请人： Intercept Pharmaceuticals Inc.

发明人： PELLICCIARI, Roberto ,  FIORUCCI, Stefano ,  PRUZANSKI, Mark

IPC分类号： C07J9/00 ,  A61K31/575 ,  C07J31/00 ,  A61P1/16

CPC分类号： A61K31/575 ,  C07J9/00 ,  C07J31/006

公开(公告)号：EP2712617A1

公开(公告)日：2014-04-02

申请号：EP13189553.4

申请日：2005-03-14

申请人： Intercept Pharmaceuticals, Inc.

发明人： Fiorucci, Stefano ,  Pelliciari, Roberto ,  Pruzanski, Mark

IPC分类号： A61K31/56

摘要： The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

公开(公告)号：EP2698375A2

公开(公告)日：2014-02-19

申请号：EP13192394.8

申请日：2009-11-19

申请人： Intercept Pharmaceuticals, Inc.

发明人： Pellicciari, Roberto

IPC分类号： C07J9/00 ,  C07J31/00 ,  C07J41/00 ,  A61K31/575 ,  A61P1/16

CPC分类号： C07J9/005 ,  C07J9/00 ,  C07J31/00 ,  C07J41/00

摘要： The invention relates to compounds of Formula A: (A) or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer and gastrointestinal disease.

公开(公告)号：EP2040713A4

公开(公告)日：2012-08-29

申请号：EP07809913

申请日：2007-06-27

申请人： INTERCEPT PHARMACEUTICALS INC

发明人： PELLICCIARI ROBERTO ,  FIORUCCI STEFANO ,  PRUZANSKI MARK

IPC分类号： C07J9/00 ,  A61K31/575 ,  A61P1/16 ,  C07J31/00

CPC分类号： A61K31/575 ,  C07J9/00 ,  C07J31/006

公开(公告)号：EP2373673A1

公开(公告)日：2011-10-12

申请号：EP09759854.4

申请日：2009-11-19

申请人： Intercept Pharmaceuticals, Inc.

发明人： PELLICCIARI, Roberto

IPC分类号： C07J9/00 ,  A61K31/575 ,  A61P3/06

CPC分类号： C07J9/005

摘要： The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease.

公开(公告)号：EP1987051A2

公开(公告)日：2008-11-05

申请号：EP07750509.7

申请日：2007-02-14

申请人： Intercept Pharmaceuticals, Inc.

发明人： PELLICCIARI, Roberto ,  FIORUCCI, Stefano ,  PRUZANSKI, Mark

IPC分类号： C07J9/00 ,  C07J41/00 ,  A61K31/56

CPC分类号： C07J41/00 ,  C07J9/00

摘要： The present invention relates to compounds of formula (I) wherein: Ri is hydrogen or an alkyl group; R2 is hydrogen or a halogen, nitro, alkyloxy, amino or carboxy group; Y is CH2, oxygen or sulfur; n is an integer from 1 to 4, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof for the treatment of FXR-mediated diseases or conditions.